AbbVie Inc.
- Last sale
- Nov 12, 2026 · -0.13%
- Market cap
- $520.54B
- 1.77B shares
- Filings
- 1,041
Q3 2026+8.6% FY25 yoy
Q3 2026−1.2% FY25 yoy
Q3 2026+65.0% FY25 yoy
Q3 2026derived−0.1% FY25 yoy
Q3 2026−1.3% FY25 yoy
Q3 2026−5.3% FY25 yoy
- $520.54B
- 50.3×
- 7.9×
- —
- 3.63%
- 2.33%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $61,160,000,000 | reported | |
| FY 2024 | 2024-12-31 | $56,334,000,000 | reported | |
| FY 2023 | 2023-12-31 | $54,318,000,000 | reported | |
| FY 2022 | 2022-12-31 | $58,054,000,000 | reported | |
| FY 2021 | 2021-12-31 | $56,197,000,000 | reported | |
| FY 2020 | 2020-12-31 | $45,804,000,000 | reported | |
| FY 2019 | 2019-12-31 | $33,266,000,000 | reported | |
| FY 2018 | 2018-12-31 | $32,753,000,000 | reported | |
| FY 2017 | 2017-12-31 | $28,216,000,000 | reported | |
| FY 2016 | 2016-12-31 | $25,638,000,000 | reported | |
| FY 2015 | 2015-12-31 | $22,859,000,000 | reported | |
| FY 2014 | 2014-12-31 | $19,960,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.66B | $980.00M | $12.64B | $6.65 | 1.77B sh | +0.2% | 70.9% |
| FY2024 | $11.03B | $1.71B | $12.73B | $6.29 | 1.77B sh | −0.1% | 71.4% |
| FY2023 | $10.54B | $1.97B | $12.51B | $5.99 | 1.77B sh | −0.2% | 56.7% |
| FY2022 | $10.04B | $1.49B | $11.53B | $5.71 | 1.77B sh | +0.0% | 47.6% |
| FY2021 | $9.26B | $934.00M | $10.20B | $5.31 | 1.77B sh | +0.2% | 46.4% |
Segments
Geography
LineFY2025ShareChange
United States$46.60B76%+8.3%
Germany$1.74B2.8%+18.6%
Japan$1.27B2.1%+13.5%
Canada$1.22B2.0%+12.3%
China$1.01B1.6%+9.7%
France$806.00M1.3%+3.9%
United Kingdom$626.00M1.0%+19.9%
Other$2.13B3.5%+8.1%
Total$61.16B
Pharmaceutical preparations
AbbVie Inc. is the 5th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JNJJohnson & Johnson$94.2B6.0%28.5%$682.6BLLYEli Lilly & Co$65.2B44.7%31.7%$1.3TMRKMerck & Co., Inc.$65.0B1.3%28.1%$362.3BPFEPfizer Inc$62.6B1.6%12.4%$164.3B
ABBVAbbVie Inc. (this company)$61.2B8.6%6.9%$520.5B
AZNAstraZeneca PLC$58.7B8.6%17.4%—BMYBristol Myers Squibb Co$48.2B0.2%14.6%$127.4BABTAbbott Laboratories$44.3B5.7%14.7%$185.8BUPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
AbbVie Inc. · CIK 1551152 · Engraved from SEC EDGAR